WuXi Biologics wins ABL Bio contract for bispecific antibodies

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Ruskpp)
(Image: Getty/Ruskpp)

Related tags: CDMO, Wuxi biologics, South korea, China

South Korean biotech ABL Bio has selected WuXi Biologics to develop and manufacture up to eight bispecific antibodies for the clinic.

ABL Bio Corporation’s bispecific antibodies, which bind two different epitopes either on the same or different targets, are being developed for immune-oncology and neurodegenerative diseases.

WuXi Biologics and ABL Bio’s agreement will see the Chinese contract development and manufacturing organisation (CDMO) prepare up to eight bispecific antibodies for clinical trials.

Candidates will be selected from both ABL Bio’s pipeline and collaboration programmes​ between ABL Bio and I-Mab Biopharma.

“The partnership with WuXi Biologics is an important strategy for growing our internal and external programmes of next-generation…biologics, such as [the] bispecific antibody,” ​said ABL Bio CEO Sang Hoon Lee in a statement.

For WuXi Biologics, the exclusive partnership marks its first in South Korea. The CDMO is expanding internationally, with an estimated capacity of 220,000 litres planned across China, Ireland​, Singapore​, and the US​ by 2021.

Earlier this month, the firm broke ground​ on its eight drug substance manufacturing facility – located in China’s Hebei province – and announced plans​ to build a discovery, development and manufacturing site in the Fengxian district of Shanghai.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars